BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Background:
Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low-frequency T cells such as BKV-specific T cells.
Case report:
Here, we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV-specific T cells using the new second-generation CliniMACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications.
Conclusion:
Our observations suggest that use of products enriched with BKV-specific T cells generated using this system is safe and efficient in HLA-haploidentical HCT where BKV cystitis can be a serious complication.
Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low-frequency T cells such as BKV-specific T cells.
Case report:
Here, we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV-specific T cells using the new second-generation CliniMACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications.
Conclusion:
Our observations suggest that use of products enriched with BKV-specific T cells generated using this system is safe and efficient in HLA-haploidentical HCT where BKV cystitis can be a serious complication.
Date Issued
2017-03-01
Date Acceptance
2017-01-09
Citation
EUROPEAN JOURNAL OF HAEMATOLOGY, 2017, 98 (6), pp.632-634
ISSN
0902-4441
Publisher
WILEY
Start Page
632
End Page
634
Journal / Book Title
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume
98
Issue
6
Copyright Statement
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. This is the accepted version of the following article: Pello OM, Innes A, Bradshaw A, et al. BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur J Haematol. 2017;98:632–634, which has been published in final form at https://dx.doi.org/10.1111/ejh.12848
Sponsor
Medical Research Council (MRC)
National Institute for Health Research
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000403724100013&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
MC_G0802523
NF-SI-0611-10275
Subjects
Science & Technology
Life Sciences & Biomedicine
Hematology
BK virus
donor-specific T cells
HLA transplantation
CliniMACS Prodigy
case report
adoptive transfer
1102 Cardiovascular Medicine And Haematology
Immunology
Publication Status
Published